Tolerion has a novel, patented drug in Phase 2 that has potential for being the first disease modifying therapy in type 1 diabetes.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free